SIR-Antipsychotics are the cornerstone of pharmacological treatment of delirium [1] . In case reports, cholinesterase inhibitors can improve (Wengel 1998 [2]), reverse (Fisher 2001 [3] ) and prevent (Dautzenberg 2003 [4] ) delirium. The question remains whether, in the case of ineffectiveness of antipsychotics, cholinesterase inhibitors can be used in the treatment of a chronic delirium.
We present a retrospective study of the efficacy of rivastigmine, a cholinesterase inhibitor, in the treatment of a chronic delirium on non-geriatric wards of a 1,120 bed teaching hospital in the period from January 2002 until June 2003.
In our hospital, non-pharmacological supportive environmental measures to prevent a delirium are offered for high-risk patients by protocol. The primary responsible (non-geriatric) physician sometimes starts low dose haloperidol. However, in most of these cases the geriatric consultation team (GCT, consisting of a geriatric specialist nurse, a geriatric resident and a geriatric consultant) diagnoses delirium, based on DSM-IV criteria. This GCT coordinates and initiates the treatment of a delirium on daily visits. In the case of a chronic delirium, non-responsive to antipsychotics, the geriatric consultant is the only person who initiates rivastigmine in these patients.
Due to the retrospective character for this study, the end of the delirium was determined as the start of a period of 2 consecutive nights without a sleep disorder probably due to delirium. Medical psychosocial characteristics of the patients and the studied predisposing and precipitating factors for a delirium are presented in Table 1 .
Related to delirium, the GCT treated a total of 366 patients in the study period. Thirty-two patients were treated with rivastigmine, but 11 patients started with rivastigmine pre-admission. Therefore, the experimental group (Group R) consisted of 21 patients (5.8%). Of the remaining 334 patients, a control group of 29 patients was selected at random. Differences between incidence rates of delirium in rivastigmine users and controls and between means of patient and delirium characteristics were tested by comparing 95% confidence intervals. All variables were tested for normality. In Group R, more patients were married, more patients were demented and more patients had infections.
In all but one patient (95%), the GTC added rivastigmine to the current antipsychotic treatment regimen. Mean duration of delirium before starting rivastigmine treatment was 28 days. Only in 1 patient was rivastigmine the drug of first choice and was used as a monotherapy in a somnolent delirium due to cerebral hypoxia. This patient recovered after 19 days of rivastigmine at a dose of 6 mg/day.
In total, 15 out of the 21 patients (71.4%) recovered from their delirium after starting rivastigmine, with an average of 12.6 days (8.4−33.6). Dosages of rivastigmine varied from 3-9 mg/day at the time of response. Non-responders had a bad prognosis. Three of these 6 patients died. In Group R, 8 patients were treated for delirium directly related to brain disorders on the neurological department. Of these 8 patients, 50% were non-responders.
As a result of non-response of the antipsychotic treatment, compared to Group C, the delirium in Group R had a longer duration (respectively 5.3 versus 40.8 days; P < 0.0001), needed a longer treatment by the GCT (12.2 versus 45.0 days; P < 0.0001); the patient stayed longer in the hospital (28.4 versus 75.9 days; P < 0.0001) and had less non-residential care after discharge (55.6% versus 9.5%; P < 0.05) (for details of the incidence and the outcome of delirium see Appendix 1 in the supplementary data on the journal website http:// www.ageing.oupjournals.org).
The retrospective design for a study looking at drug outcomes is filled with serious deficiencies and potential flaws. However, adding rivastigmine to antipsychotic treatment for a chronic delirium might be potentially successful, because a positive response was observed in 71.4% of the cases treated, although still a minority of these patients was discharged to non-residential care. Non-response for rivastigmine implied a bad prognosis and seemed to occur preferentially in patients with neurological diseases. A silent ageism in access to critical care SIR-We read, with great interest, the article by Hubbard et al. [1] on the absence of ageism in access to critical care and would like to comment on their results and record our experience. In order to solve the problem of elderly patients admitted to our emergency room and who are in need of intensive care, the Board of our 350-bed hospital set up, at the beginning of 2003, a 4-bed sub-intensive care unit (SICU) for elderly patients within the geriatric department. In fact, the existing 8-bed intensive care unit (ICU) in the hospital had become progressively inadequate to support the needs of all the patients with critical medical conditions, of which the majority were elderly.
During 2003, the number of patients over 75 years of age admitted to the emergency room was similar to the previous year (1, As shown in Table 1 , the patients treated in our SICU were old, with several co-morbidities and a high burden of disease and disability. The clinical data, in-hospital mortality, and 3-month survival rate clearly indicate the appropriateness of elderly patients managed in the SICU.
We ask the question as to whether, before the opening of the SICU, did most of the elderly patients admitted to the hospital receive adequate care?
It is our opinion that ageism is not usually an open discriminator against the elderly, but rather a lack of response to the rapid demographic changes and the current needs of an ageing population.
In this perspective, the data by Hubbard et al. are extremely helpful in supporting changes in critical care bed provision for older people here in Italy and we have in the last 12 months already started on a local scale in our hospital. 
